Frontier Capital Management CO LLC Iovance Biotherapeutics, Inc. Transaction History

Frontier Capital Management CO LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$9.53 - $13.11 $621,918 - $855,545	65,259 Added 20.56%	382,648 $3.67 Million
Q2 2022 Jul 20, 2022	SELL	$6.38 - $18.33 $713,724 - $2.05 Million	-111,869 Reduced 26.06%	317,389 $3.5 Million
Q1 2022 Apr 14, 2022	SELL	$12.38 - $19.1 $1.34 Million - $2.06 Million	-108,039 Reduced 20.11%	429,258 $7.15 Million
Q4 2021 Jan 19, 2022	SELL	$16.55 - $27.63 $2.31 Million - $3.86 Million	-139,645 Reduced 20.63%	537,297 $10.3 Million
Q3 2021 Oct 19, 2021	SELL	$20.35 - $26.63 $6.88 Million - $9 Million	-337,871 Reduced 33.29%	676,942 $16.7 Million
Q2 2021 Aug 09, 2021	BUY	$16.33 - $33.07 $16.6 Million - $33.6 Million	1,014,813 New	1,014,813 $26.4 Million

314

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.35B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Frontier Capital Management CO LLC, based on Form 13F filings with the SEC.

Stay updated on Frontier Capital Management CO LLC with notifications on news.